563 related articles for article (PubMed ID: 28634699)
1. Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
Syngle A; Kaur S; Verma I; Syngle T; Syngle V
Clin Rheumatol; 2017 Aug; 36(8):1715-1720. PubMed ID: 28634699
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
[TBL] [Abstract][Full Text] [Related]
3. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
4. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
6. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
[TBL] [Abstract][Full Text] [Related]
8. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study.
Guin A; Chatterjee Adhikari M; Chakraborty S; Sinhamahapatra P; Ghosh A
Semin Arthritis Rheum; 2013 Aug; 43(1):48-54. PubMed ID: 23415602
[TBL] [Abstract][Full Text] [Related]
9. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
Puolakka K; Kautiainen H; Mottonen T; Hannonen P; Korpela M; Hakala M; Luukkainen R; Vuori K; Blåfield H; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(2):96-103. PubMed ID: 19274516
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis.
Osiri M; Kamolratanakul P; Maetzel A; Tugwell P
Rheumatol Int; 2007 Sep; 27(11):1063-9. PubMed ID: 17440729
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months.
Bae SC; Cho SK; Won S; Lee HS; Lee SH; Kang YM; Lee SH; Lee YA; Choe JY; Chung WT; Suh CH; Shim SC; Lee J; Yoon BY; Kim DW; Lee SS; Yoo WH; Kim JS; Jung YO; Nah SS; Lee CK; Song GG; Choi SJ; Joung CI; Koh H; Kim YJ
Int J Rheum Dis; 2018 May; 21(5):1001-1009. PubMed ID: 29878615
[TBL] [Abstract][Full Text] [Related]
12. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
[TBL] [Abstract][Full Text] [Related]
13. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
[TBL] [Abstract][Full Text] [Related]
15. Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up.
Graell E; Vazquez I; Larrosa M; Rodríguez-Cros JR; Hernández MV; Gratacós J; Gómez A; Cañete JD; Gómez-Puerta JA; Sanmartí R
Clin Exp Rheumatol; 2009; 27(2):284-91. PubMed ID: 19473570
[TBL] [Abstract][Full Text] [Related]
16. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
17. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
[TBL] [Abstract][Full Text] [Related]
18. Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice.
Osiri M; Deesomchok U; Tugwell P
Clin Rheumatol; 2006 Sep; 25(5):721-7. PubMed ID: 16365685
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of disease modifying anti-rheumatic drugs in rheumatoid arthritis in local patients of Karachi.
Baig MS; Humail SM; Zaidi SI; Noor S; Bano S; Rehman S; Fawwad A
Pak J Biol Sci; 2009 Feb; 12(4):339-45. PubMed ID: 19579967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
